867162-54-7Relevant academic research and scientific papers
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
Mulvihill, Mark J.,Ji, Qun-Sheng,Coate, Heather R.,Cooke, Andrew,Dong, Hanqing,Feng, Lixin,Foreman, Kenneth,Rosenfeld-Franklin, Maryland,Honda, Ayako,Mak, Gilda,Mulvihill, Kristen M.,Nigro, Anthony I.,O'Connor, Matthew,Pirrit, Caroline,Steinig, Arno G.,Siu, Kam,Stolz, Kathryn M.,Sun, Yingchuan,Tavares, Paula A.R.,Yao, Yan,Gibson, Neil W.
, p. 1359 - 1375 (2008/09/19)
A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR (IGF-1R) inhibitors-most notably, cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine (AQIP)-is described. Synthetic details, structure
6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS
-
Page/Page column 232-233, (2008/06/13)
Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein XI, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
